BioSpace News Archive

Codexis, Inc., a leading enzyme engineering company, announced an update on the Company’s ongoing plan to prioritize its time and resources on areas where the Company believes it has the strongest commercial opportunity and greatest probability of success.

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today hosted an R&D Showcase providing an extensive overview of pipeline advances from three clinical stage AlloCAR T programs.

Eargo, Inc., a medical device company on a mission to improve the quality of life of people with hearing loss, is pleased to announce that Patient Square Capital has become the majority equity owner of the Company.

Myriad Genetics, Inc., (NASDAQ: MYGN) a leader in genetic testing and precision medicine, today announced multiple presentations of new data at the 2022 San Antonio Breast Cancer Symposium (SABCS), including a spotlight discussion on breast cancer risk prediction.

Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on rare endocrine disorders, announced that the Company will host two key opinion leaders in the field of pediatric endocrinology for a discussion of interim data from our Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials evaluating oral LUM-201 in Pediatric Growth Hormone Deficiency (PGHD).

MedGene Therapeutics, Inc. (MedGene), a biopharmaceutical company dedicated to bringing adoptive cell therapies to solid tumors, today announced the publication of a peer-reviewed article titled “Krüppel-like factor 4 regulates the cytolytic effector function of exhausted CD8 T cells” (https://www.science.org/doi/epdf/10.1126/sciadv.adc9346).

Eisai Co., Ltd. and Biogen Inc. announced that the results from Eisai’s large global Phase 3 confirmatory Clarity AD clinical study of lecanemab, an investigational anti-amyloid beta protofibril antibody for the treatment of mild cognitive impairment due to Alzheimer’s disease and mild AD with confirmed presence of amyloid pathology in the brain, were presented at the 2022 Clinical Trials on Alzheimer’s Disease conference, in San Francisco, California and virtually.

The Alzheimer’s Association welcomes and is further encouraged by the full Phase 3 data presented by Eisai and Biogen from the CLARITY AD global Phase 3 clinical trial of lecanemab.

BioArctic AB’s partner Eisai announced that the results from the large global Phase 3 confirmatory Clarity AD clinical study of lecanemab, an investigational anti-amyloid beta protofibril antibody for the treatment of mild cognitive impairment due to Alzheimer’s disease and mild AD with confirmed presence of amyloid pathology in the brain, were published in the New England Journal of Medicine, one of the world’s most prestigious peer-reviewed medical journals.

Seven abstracts related to the Company’s work in Dravet syndrome will be presented, including data from a combined interim analysis of the Phase 1/2a MONARCH and ADMIRAL studies of STK-001.